IPP Bureau

Ind-Swift Laboratories receives award from World HRD Congress
Ind-Swift Laboratories receives award from World HRD Congress

By IPP Bureau - December 25, 2023

World HRD Congress is a well-known international body of Management Studies

Lyndra Therapeutics raises US$101 million in Series E funding
Lyndra Therapeutics raises US$101 million in Series E funding

By IPP Bureau - December 25, 2023

Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners

Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion
Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion

By IPP Bureau - December 24, 2023

Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety

Biocon Biologics signs distribution partnership with Sandoz for Adalimumab BS Subcutaneous Injection in Japan
Biocon Biologics signs distribution partnership with Sandoz for Adalimumab BS Subcutaneous Injection in Japan

By IPP Bureau - December 23, 2023

The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio

Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA
Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA

By IPP Bureau - December 23, 2023

This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023

Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi
Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi

By IPP Bureau - December 23, 2023

The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired

USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer
USFDA grants priority review for Patritumab Deruxtecan in US for certain patients with EGFR-mutated non-small cell lung cancer

By IPP Bureau - December 23, 2023

If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients

UPM Biomedicals enters into distribution agreement with Brinter for GrowInk bioinks
UPM Biomedicals enters into distribution agreement with Brinter for GrowInk bioinks

By IPP Bureau - December 23, 2023

The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries

Natco Pharma and Breckenridge dismissed from antitrust lawsuit
Natco Pharma and Breckenridge dismissed from antitrust lawsuit

By IPP Bureau - December 22, 2023

Ami Organics inks MoU with a global manufacturer of electrolytes
Ami Organics inks MoU with a global manufacturer of electrolytes

By IPP Bureau - December 22, 2023

Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business

Strides Pharma Science extends guarantee to Trinity Pharma Proprietary’s borrowing
Strides Pharma Science extends guarantee to Trinity Pharma Proprietary’s borrowing

By IPP Bureau - December 22, 2023

Trinity has availed credit facility from Investec for Business for their working capital requirements of Rs. 31.5 crore

Lupin launches liquid fibre Softovac Liquifibre
Lupin launches liquid fibre Softovac Liquifibre

By IPP Bureau - December 22, 2023

Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients

JB Pharma buys opthalmology brands from Novartis for Rs 964 Cr
JB Pharma buys opthalmology brands from Novartis for Rs 964 Cr

By IPP Bureau - December 22, 2023

JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market

Abbott India MD Vivek Kamath resigns
Abbott India MD Vivek Kamath resigns

By IPP Bureau - December 22, 2023

His resignation would be effective from March 18, 2024

Digital transformation key to managing rising organisational healthcare costs in India
Digital transformation key to managing rising organisational healthcare costs in India

By IPP Bureau - December 22, 2023

Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024

Latest Stories

Interviews

Packaging